Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) and Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Valuation and Earnings
This table compares Werewolf Therapeutics and Prelude Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Werewolf Therapeutics | $1.88 million | 10.46 | -$60.82 million | ($0.76) | -0.53 |
| Prelude Therapeutics | $12.14 million | 36.41 | -$99.50 million | ($0.73) | -7.60 |
Institutional and Insider Ownership
64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Werewolf Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
Profitability
This table compares Werewolf Therapeutics and Prelude Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Werewolf Therapeutics | N/A | -166.99% | -59.88% |
| Prelude Therapeutics | N/A | -75.35% | -44.39% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Werewolf Therapeutics and Prelude Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Werewolf Therapeutics | 1 | 4 | 2 | 0 | 2.14 |
| Prelude Therapeutics | 1 | 1 | 3 | 0 | 2.40 |
Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 826.61%. Prelude Therapeutics has a consensus price target of $7.67, indicating a potential upside of 38.14%. Given Werewolf Therapeutics’ higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Prelude Therapeutics.
Summary
Prelude Therapeutics beats Werewolf Therapeutics on 10 of the 13 factors compared between the two stocks.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
About Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
